The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
Conferences AACR 2019: Two KEYNOTE trials show pembrolizumab benefit for advanced SCLC April 6, 2019 The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumour activity with durable responses in patients…